Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis